Examining the effect of the anti inflammatory medicine prednisolone on physical performance in patients with COPD and changes in immune response after exercise

Effect of Glococorticosteroids on physical performance in patients with chronic obstructive pulmonary disease and acute inflammatory response after exercise

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-004503-13-DK

Enrollment

Registered

2013-01-18

Start date

2012-12-12

Completion date

Unknown

Last updated

2013-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

To investigate the effects of prednisone and Solu-Medrol on physical performance in patients with chronic obstructive pulmonary disease(COPD). Furthermore to examine the inflammatory response during and after exercise in patients with COPD

Interventions

Trade Name: Prednisolone Product Name: Prednisolone Product Code: H02AB07 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: sex: male age 40-75 FEV1=65 years) yes F.1.3.1 Number of subjects for this age range 7

Exclusion criteria

Exclusion criteria: haemodynamicaly unstable heart conditions ie heart failure, atrial fibrilation and angina pectoris other respiratory diseases cancer the last 5 years treatment with beta blockers allergi to study medication insuline treated diabetes

Design outcomes

Primary

Measure	Time frame
Main Objective: The purpose of this trial is to investigate the effects of the drugs prednisone and Solu-Medrol on physical performance in patients with COPD;Secondary Objective: To examine the inflammatory response during and after exercise in patients with COPD;Primary end point(s): prednisone and solumedrol improves cycling performance;Timepoint(s) of evaluation of this end point: 1,5 years from first participant	—

Measure

Time frame

Main Objective: The purpose of this trial is to investigate the effects of the drugs prednisone and Solu-Medrol on physical performance in patients with COPD;Secondary Objective: To examine the inflammatory response during and after exercise in patients with COPD;Primary end point(s): prednisone and solumedrol improves cycling performance;Timepoint(s) of evaluation of this end point: 1,5 years from first participant

—

Secondary

Measure	Time frame
Secondary end point(s): prednisonae and Solu-Medrol improves muscle power. to examine the inflammatory response during exercise during treatment with glucocorticoids;Timepoint(s) of evaluation of this end point: 1,5 years	—

Countries

Denmark

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026